- Open Access
Optimization of FDG-PET/CT imaging protocol for evaluation of patients with primary and metastatic liver disease
© Kuker et al; licensee BioMed Central Ltd. 2007
Received: 11 May 2007
Accepted: 10 July 2007
Published: 10 July 2007
Accurate determination of the extrahepatic extent and intrahepatic distribution of disease is very important in patients with primary and metastatic liver disease for deciding whether a patient receives potentially curable surgery or palliative treatment. Our objective was to evaluate the efficacy of delayed phase FDG-PET/CT imaging in lesion detection and to define its clinical impact compared to triple-phase contrast enhanced CT (CECT).
30 patients underwent delayed phase FDG-PET/CT imaging (90 min whole body scan followed by a delayed abdominal scan at 120 min). Maximum standard uptake values (SUVs) and SUV ratios between tumor and normal liver parenchyma (T/N) were evaluated. In addition, comparison was made to CECT obtained within 10 days of the FDG-PET/CT to evaluate for lesion concordance within individual liver segments (Couinaud designation).
Sites of primary malignancies included: colorectal (19), breast (3), pancreas (2), lung (2), carcinoid (2), cholangiocarcinoma (1), and hepatocellular carcinoma (1). There was a significant increase in SUV value of liver lesions between early and delayed acquisition (P < 0.001). Although there was not a significant reduction in liver background activity between the two studies, there was a strong increase in T/N ratio (P < 0.001) allowing better lesion detection by visual inspection. New lesions were identified in 5 of the 30 patients, which were not appreciated on the early scan. Delayed phase FDG-PET/CT identified one lesion which was not present on the corresponding CECT. Delayed phase FDG-PET/CT revealed extrahepatic sites of metastases not appreciated on CECT in 6 patients.
Delayed phase FDG-PET/CT protocol improved lesion detectability in primary and metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT identified extrahepatic disease not seen on CECT in 20% of the patients.
The liver is a frequent site of hematogenous metastases because of its rich dual blood supply. Local endocrine factors that promote cell growth and fenestrations in the sinusoidal endothelium allow tumor emboli arriving via the blood stream to implant and multiply within the space of Disse . Common gastrointestinal (GI) malignancies that metastasize to the liver include colonic, pancreatic, gastric, gallbladder, and neuroendocrine tumors. Previously, patients who presented with liver metastases were classified as stage IV disease and treatment was met with great skepticism. However, advances in surgical and medical therapies over the past two decades have provided effective treatment options. Improvements in surgical technique combined with a better understanding of intrahepatic anatomy have allowed hepatic resections to be performed with acceptable morbidity. Major hepatobiliary centers routinely report less than 5% perioperative mortality for non-cirrhotic patients undergoing partial hepatectomy .
Anatomic resection of liver metastases is now commonly performed in colorectal cancer patients with isolated intrahepatic disease, and the impact has been dramatic with five year survival rates up to 40% . Patients with extrahepatic metastases that are amenable to resection may also benefit from partial hepatectomy and can achieve five year survival rates of 28% as reported by Elias et al . Similar results have been demonstrated in resection of primary liver tumors. Tanaka et al reports three year survival rates of 89% after partial hepatectomy for hepatocellular carcinoma meeting Milan criteria (solitary tumor < 5 cm or up to three nodules < 3 cm) . Surgical resection of large hepatocellular carcinomas > 10 cm have less impressive outcomes but still can achieve five year survival rates up to 28% .
Radiologic staging of patients with primary or metastatic liver disease is vital to determine the suitability of partial hepatectomy [7–9]. The goals of imaging are twofold: define the extrahepatic extent and intrahepatic distribution of disease. Triple-phase contrast enhanced CT (CECT) has been the mainstay of preoperative planning by providing key anatomical information. MRI can provide complementary data by evaluating the signal and enhancement characteristics of liver lesions and may better delineate involvement/invasion into adjacent vascular or biliary structures. MRI, however, has low sensitivity for detecting extrahepatic disease.
PET/CT with 18F-FDG is an integral tool for the staging of many malignancies. PET/CT has been shown to improve the therapeutic management of patients with colorectal cancer by detecting unsuspected extrahepatic metastases [10–16]. The value of PET/CT has been questioned for detection of intrahepatic disease because of the high background activity in the liver parenchyma due to high glucose metabolism and abundant expression of Glut-1 and hexokinase II (HK-II). To circumvent the problems inherent to detection of intrahepatic lesions on PET/CT, several authors have proposed delayed PET/CT imaging and the results have been encouraging [17–21]. The premise of dual phase PET/CT is that malignant cells should preferentially accumulate activity more than normal hepatocytes thereby improving tumor to background ratios over time. Our goal was to determine whether dual phase acquisition PET/CT can improve lesion detectability in primary and metastatic liver disease and to define its clinical impact compared to CECT.
149 consecutive cancer patients evaluated at the Goshen Cancer Institute over a six month period underwent dual phase 18F-FDG PET/CT imaging. The studied patients had known primary malignancies either hepatic in origin or extrahepatic with suspected liver metastases.
Patients were asked to fast for a minimum of six hours prior to the study and blood glucose levels had to be less than 200 mg/dl prior to injection of 18F-FDG. All images were acquired using a dedicated GE Discovery PET/CT scanner. Initial "early" whole body imaging commenced 90 ± 15 minutes after injection of 15 mCi of 18F-FDG. An additional "delayed" scan focusing on the liver was obtained 120 ± 16 minutes after the injection. PET images were reconstructed using CT attenuation correction, dead time correction, and decay correction to the beginning of each scan.
Early and delayed images were interpreted on the GE workstation in the axial, coronal, and sagittal planes along with maximum intensity projection images. Each scan was reviewed for the presence of liver lesions. Maximum standardized uptake values (SUVs) were obtained by drawing three dimensional regions of interest (ROIs) around each lesion on the early study and the corresponding lesion on the delayed study. Lesions which demonstrated SUVs greater than background activity with a minimum value of 3 were defined as positive for metastasis. ROIs were also placed over uninvolved regions of the liver to obtain SUVs of the background normal liver parenchyma. The tumor to normal parenchyma ratio (T/N ratio) was then calculated for each lesion identified on the early and delayed studies using the following formulas:
T/N early = SUV tumor early /SUV background early
T/N delayed = SUV tumor delayed /SUV background delayed
Paired T-Test was used for statistical comparison of early and delayed tumor SUV values, background SUV values, and T/N ratios. P values less than 0.05 were considered statistically significant for all analyses.
In addition to ROI analysis, comparison was made to CECT obtained within 10 days of the PET/CT to evaluate for the following parameters: lesion concordance within individual liver segments (Couinaud designation) and extrahepatic sites of metastases.
30 of the 149 patients demonstrated liver lesions (13 males and 17 females, mean age 61.1 years, age range 42–86 years). Sites of primary malignancies included: colorectal (n = 19), breast (n = 3), pancreas (n = 2), lung (n = 2), carcinoid (n = 2), cholangiocarcinoma (n = 1), and hepatocellular carcinoma (n = 1).
Semi quantitative analysis of 18F-FDG uptake in metastatic liver lesions on delayed phase PET/CT.
SUV in malignant lesions
10.2 ± 4.8
11.3 ± 5.0
SUV in normal parenchyma
3.7 ± 0.8
3.4 ± 0.8
2.9 ± 1.5
3.4 ± 1.5
18F-FDG PET/CT is a valuable tool for the staging of many malignancies. Although the fusion of anatomic CT data with the functional information provided by PET has improved diagnostic accuracy, detection of primary and metastatic liver lesions remains challenging because of the high background FDG activity in normal liver parenchyma and reconstruction artifacts generated by respiratory diaphragmatic motion. FDG uptake in normal and malignant tissues is dependent on a variety of factors. On a macroscopic level, malignant cells metabolize glucose at increased levels because of high energy demands and therefore show PET positivity since FDG is used as an energy substrate. More aggressive tumors have higher energy demands and higher metabolic rates and tend to be strongly positive on PET. On a molecular level, it is the expression of Glut 1 and HK-II that allows FDG to enter the cell, become phosphorylated, and then trapped intracellularly allowing for coincidence detection of positron emissions. It has been suggested that Glut-1 and HK-II expression are inversely related in some primary liver tumors . Cells that have high levels of Glut-1 such as mass-forming cholangiocarcinoma can easily facilitate glucose transport into the cell. High intracellular levels of glucose-6-phosphate may cause downregulation of HK-II by feedback inhibition. On the other hand, HK-II expression in high grade hepatocellular carcinoma (HCC) is elevated likely a result of upregulation caused by low levels of Glut-1 on the cell surface. Both cholangiocarcinoma and high grade HCC are strongly PET positive; and although they may have different mechanisms of FDG uptake, they have a final common pathway of increased glucose metabolism.
Is there a molecular explanation of why delayed imaging may facilitate tumor detection and why SUV values increase over time in malignant cells? The answer may lie in tumor vascularity. It has been demonstrated that Glut-1 and HK-II expression is greatest in the central region of tumors by autoradiography . Aggressive tumors often have insufficient blood supply leading to hypoxia and eventual central necrosis. When tumor cells are exposed to a hypoxic environment, HIF-1α is activated to promote the transcription of glucose transporters and glycolytic enzymes. Delayed imaging allows more time for FDG to migrate to hypoxic areas which have higher regional levels of Glut-1 and HK-II. Delayed imaging also allows more time for FDG to reach hypovascular tumors or those with altered blood supply as a sequella of prior treatments. Finally, delayed imaging allows for further clearance of blood pool activity.
Dual phase 18F-FDG PET has been proposed by other authors for the evaluation of GI malignancies and the results have been encouraging. Nishiyama et al. reports increased lesion uptake and increased lesion-to-background contrast in gallbladder carcinoma on delayed images; however, the diagnostic performance was dependent on C-reactive protein levels . Nishiyama also reports that delayed FDG PET is helpful in pancreatic cancer by identifying new metastatic foci in 3 of 55 patients . In a study of 12 patients with hepatocellular carcinoma, Lin et al. found that the mean SUV, T/N ratio, and diagnostic sensitivity all increased on 2 hour delayed images. Lin et al. also showed a slight decrease in the mean SUV of normal liver tissue . Our study did not show a significant difference between early and delayed background liver activity; however, this variability in background activity had little impact on T/N ratios which still increased in 86% of metastatic lesions our study. This suggests that it is the retention of FDG in malignant cells (as determined by Glut-1 and HK-II expression) rather than clearance of blood pool activity that is the most important factor in delayed lesion detection. This observation, however, needs to be correlated with biochemical analysis.
If dual phase PET/CT can improve the detection of primary and metastatic liver lesions as we have demonstrated, should all patients requiring PET/CT for staging purposes undergo dual phase acquisition? In an era where curative liver resections are increasingly performed, appropriate selection of patients for this clinical objective is imperative. The most important information provided by radiologic studies, obviously, is to determine whether an R0 curative resection can be safely performed by identifying the number and distribution of lesions and their proximity to major vascular structures and the biliary tree. In this respect, accurate staging of patients with identification of hepatic and extrahepatic distribution of lesions is very important. The ultimate answer to this question could require prospective studies with larger patient populations addressing comprehensive cost-benefit analyses. Based on the data that is available at this time, we propose that those patients who are candidates for surgical resection should undergo dual phase PET/CT with 18F-FDG for the following reasons. Dual phase acquisition can evaluate the metabolic activity of lesions seen on anatomical imaging and confirm benign or malignant etiology. Dual phase PET/CT may identify new metastatic lesions (intra or extrahepatic) that were not appreciated on conventional imaging modalities. In addition, dual phase PET/CT may further characterize the response of malignant lesions to neoadjuvant therapy. All of these considerations have a great impact on surgical planning and may decide whether a patient is a candidate for curative resection or whether the patient would benefit from medical therapy, decisions which are paramount for patient care and long term survival.
Delayed phase FDG-PET/CT improves lesion detectability in primary and metastatic liver disease, revealing new lesions in 17% of the patients. Moreover, FDG-PET/CT identified extrahepatic sites of metastases not seen on CECT in 20% of the patients. For these reasons, we propose that patients with primary or metastatic liver disease in whom surgical resection is being contemplated should undergo staging with delayed phase FDG-PET/CT.
The authors would like to acknowledge David A. Slabaugh for providing technical assistance in image acquisition and for his substantial contribution to the collection of data.
- Khan AN, Macdonald S, Pankhania A, Sherlock D: Liver Metastases. Emedicine. Nov 21 2003, [http://www.emedicine.com/radio/topic394.htm]
- Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 cases over the past decade. Ann Surg. 2002, 236: 397-406. 10.1097/00000658-200210000-00001.PubMed CentralView ArticlePubMedGoogle Scholar
- Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002, 235: 759-66. 10.1097/00000658-200206000-00002.PubMed CentralView ArticlePubMedGoogle Scholar
- Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, Pignon JP, Ducreux M: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol. 2004, 11: 274-80. 10.1245/ASO.2004.03.085.View ArticlePubMedGoogle Scholar
- Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S: Outcomes and recurrence of initially resectable HCC meeting Milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007, 204: 1-6. 10.1016/j.jamcollsurg.2006.10.004.View ArticlePubMedGoogle Scholar
- Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J: Hepatic resection for large hepatocellular carcinoma. Am J Surg. 2001, 181: 347-53. 10.1016/S0002-9610(01)00584-0.View ArticlePubMedGoogle Scholar
- Bentrem DJ, Dematteo RP, Blumgart LH: Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005, 56: 139-56. 10.1146/annurev.med.56.082103.104630.View ArticlePubMedGoogle Scholar
- Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW: Guidelines for resection of colorectal cancer liver metastases. Gut. 2006, 55 (Suppl III): iii1-iii8. 10.1136/gut.2006.098053.PubMed CentralPubMedGoogle Scholar
- Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D: Resection of the liver for colorectal carcinoma metastases: multi-institutional study of indications for resection. Surgery. 1988, 103: 278-88.Google Scholar
- Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ: The impact of FDG PET in the management of colorectal liver metastases. Cancer. 2005, 104 (12): 2658-70. 10.1002/cncr.21569.View ArticlePubMedGoogle Scholar
- Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC: The use of FDG PET for the evaluation of colorectal metastases of the liver. Am Surg. 1999, 65 (12): 1183-5.PubMedGoogle Scholar
- Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR: Prospective evaluation of the impact of FDG PET of respectable colorectal liver metastases. Br J Surg. 2005, 92 (3): 362-9. 10.1002/bjs.4843.View ArticlePubMedGoogle Scholar
- Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FH, Oyen WJ: Value of FDG PET in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002, 20 (2): 388-95. 10.1200/JCO.20.2.388.View ArticlePubMedGoogle Scholar
- Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D: Survival of patients evaluated by FDG PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001, 233 (3): 293-9. 10.1097/00000658-200103000-00001.PubMed CentralView ArticlePubMedGoogle Scholar
- Khan S, Tan YM, John A, Isaac J, Singhvi S, Guest P, Mirza DF: An audit of fusion PET/CT in the management of colorectal liver metastases. Eur J Surg Oncol. 2006, 32 (5): 564-7. 10.1016/j.ejso.2006.02.003.View ArticlePubMedGoogle Scholar
- Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, Satoh K, Ohkawa M: Dual time point FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006, 47 (4): 633-8.PubMedGoogle Scholar
- Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, Ohkawa M: Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumor. Nucl Med Commun. 2005, 26 (10): 895-901. 10.1097/00006231-200510000-00008.View ArticlePubMedGoogle Scholar
- Lin WY, Tsai SC, Hung GU: Value of delayed F-18 FDG PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005, 26 (4): 315-21. 10.1097/00006231-200504000-00003.View ArticlePubMedGoogle Scholar
- Koyama K, Okamura T, Kawabe J, Ozawa N, Higashiyama S, Ochi H, Yamada R: The usefulness of FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med. 2002, 16 (3): 169-76.View ArticlePubMedGoogle Scholar
- Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T: Dual phase FDG PET as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005, 32 (4): 389-97. 10.1007/s00259-004-1656-0.View ArticlePubMedGoogle Scholar
- Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, Ko D, Kim TS, Cho AE, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH: Different glucose uptake and glycolytic mechanisms between HCC and intrahepatic mass forming cholangiocarcinoma with increased FDG uptake. J Nucl Med. 2005, 46: 1753-59.PubMedGoogle Scholar
- Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N: Biologic correlates of intratumoral heterogeneity in FDG distribution with regional expression of glucose transporters and HK-II in experimental tumor. J Nucl Med. 2005, 46: 675-82.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.